Effect of siRNA-mediated LGR5 Inhibition on the Expression of Stemness-related Genes in Triple-negative Breast Cancer Spheroid Model.
Ghobakhloo S., Jafarpour S., Nedaeinia R., Salehi R.
Laboratory Study, published in Adv Biomed Res (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Adv Biomed Res (2025)
- Country
- India
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41669287
- DOI
- 10.4103/abr.abr_124_24
Abstract (original English)
Approximately 10%-15% of all breast cancer diagnoses are identified as triple-negative breast cancer (TNBC), a subtype known for its poor prognosis due to chemoresistance. TNBC lacks any receptors or proteins that are overexpressed, thus lacking targeted therapy. The protein LGR5 , a marker for cancer stem cells and a promoter of Wnt signaling pathway activity, is notably upregulated in TNBC cases. LGR5 plays an important role in chemoresistance and tumorigenesis. Considering this, our research aim was to investigate the effect of LGR5 suppression by using specific siRNA in multicellular spheroid of the TNBC cell line and evaluation of stemness-related gene expression changes. Multicellular spheroids of the MDA-MB-231 TNBC cell line were prepared. The exosome was extracted from the human adipose mesenchymal stem cells (ADMSCs) and confirmed. Multicellular spheroids were separately transfected with siRNA, EXO-siRNA and, treated with cisplatin alone. Gene expression was studied using qRT-PCR. Our findings revealed that inhibiting LGR5 with siRNA significantly reduces LGR5 expression. Furthermore, the results indicated a notable increase in the expression of stemness markers ( SOX9 , OCT4 , and NANOG ) in samples treated with cisplatin. However, the reduction of LGR5 expression via siRNA led to a marked decrease in SOX9 and OCT4 levels, while NANOG expression remained largely unch
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.